title: Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
abstract: Conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) has become an option in patients with chronic allograft nephropathy or other conditions. However, in some cases an increase of proteinuria has been reported after such therapeutic intervention. The aim of this study was to characterize the clinical course of this so far unexplained proteinuria after conversion. We performed a retrospective analysis evaluating 94 renal transplant patients from various Spanish centers. Proteinuria (629 determinations) and clinical developments were analyzed between 6 months before and 6 months after conversion. Patients were divided into three groups according to mean proteinuria before conversion (group A: <300 mg/d; group B: 300 to 2000 mg/d; and group C: >2 g/d). The mean proteinuria level was 1.69 g/24 h (n = 312 determinations) before and 2.36 g/24 h after conversion (n = 317 determinations; P = .006), which corresponds to an overall increase of 25% (1.55 to 1.69 g/24 h considering only determinations of 1 month before and 1 month after conversion; P = NS). We could not detect any clear correlation between proteinuria and serum creatinine nor between changes of proteinuria and changes of serum creatinine. A variance analysis for repeated measures showed an increase in proteinuria compared to the preconversion values (P = .003), and when the three groups of preconversion proteinuria were evaluated separately it could be observed that this change in the evolution of proteinuria was almost completely dependent of an increase in the group C (preconversion proteinuria greater than 2 g/d; P = .03), whereas in the other two groups changes were almost irrelevant. Finally, the switch to SRL in renal transplant recipients is followed by an increase in the level of proteinuria predominantly dependent of an increase in patients with high levels of preconversion proteinuria, whereas it seems to be irrelevant in patients without or with light or moderate proteinuria. These results suggest that this might not be a direct effect of SRL.
authors.affiliation: Nephrology Department, Marques de Valdecilla Hospital, University of Cantabria, Santander, Spain. ruizjc@humv.es
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
authors.forename: F
authors.initials: F
authors.lastname: Diekmann
authors.forename: J M
authors.initials: JM
authors.lastname: Campistol
authors.forename: A
authors.initials: A
authors.lastname: Sanchez-Fructuoso
authors.forename: C
authors.initials: C
authors.lastname: Rivera
authors.forename: J
authors.initials: J
authors.lastname: Oliver
authors.forename: G
authors.initials: G
authors.lastname: Fernandez-Fresnedo
authors.forename: M
authors.initials: M
authors.lastname: Arias
mesh_terms: D065095:Calcineurin Inhibitors; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D011183:Postoperative Complications / Q000453:epidemiology / Q000276:immunology / Q000652:urine; D011507:Proteinuria / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology*; D020123:Sirolimus / Q000627:therapeutic use*; D013030:Spain; D013997:Time Factors
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D020123:Sirolimus